- FSC +17% on deal for Oaktree to assume management.
- HPJ +10%.
- CTIC +9% on European marketing application for pacritinib in certain myelofibrosis patients accepted for review.
- NTNX +8% as Goldman Sachs makes a buy rating with a $31 PT.
- ACRX +7%. as Jefferies rates stock with a buy target of $7.
- MOSY +6%.
- PTX +5%.